AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33130107 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) in primary care
Number of subjects: 170
Study 33130107 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) in ob/gyn
Number of subjects: 170
Study 36064390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A with standardized compensation to the village doctors
Number of subjects: 4000
Study 36064390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B with performance-based compensation to the village doctors
Number of subjects: 4000
Study 36064390 — intervention group
Group type: COMPARATOR
Intervention: Control without mobile-based knowledge dissemination
Number of subjects: 4000
Study 32807267 — intervention group
Group type: EXPERIMENTAL
Intervention: Healive vaccine
Number of subjects: 375
Study 32807267 — intervention group
Group type: COMPARATOR
Intervention: Havrix vaccine
Number of subjects: 375
Study 35813442 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+immunoglobulin
Number of subjects: 60
Study 35813442 — intervention group
Group type: COMPARATOR
Intervention: PE
Number of subjects: 60
Study 34597297 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-GST-1 (30μg)
Number of subjects: 24
Study 34597297 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-GST-1 (100μg)
Number of subjects: 24
Study 34597297 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-APR-1
Number of subjects: 24
Study 34597297 — intervention group
Group type: COMPARATOR
Intervention: Control (Hepatitis B)
Number of subjects: 24
Study 35690697 — intervention group
Group type: EXPERIMENTAL
Intervention: RSP-TSS (Religious-Spiritual Psychotherapy based on the Twelver Shia Sects of Islam)
Number of subjects: 45
Study 35690697 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 45
Study 35690697 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 45
Study 33796993 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (0.05 to 0.4 mg/kg/h)
Number of subjects: 75
Study 33796993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 75
Study 34963186 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history only (FH only)
Number of subjects: 813
Study 34963186 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal history only (PH only)
Number of subjects: 813
Study 34963186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both family and personal history (both FH/PH)
Number of subjects: 813
Study 34963186 — intervention group
Group type: COMPARATOR
Intervention: No family/personal history (no FH/PH)
Number of subjects: 813
Study 33301221 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 13.8 g (two doses)
Number of subjects: 10
Study 33301221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg
Number of subjects: 10
Study 33301221 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 10
Study 33301221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 35112176 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-to-anterior femoral tunnel aperture position parallel to Blumensaat line
Number of subjects: 78
Study 35112176 — intervention group
Group type: COMPARATOR
Intervention: Tunnel aperture positions
Number of subjects: 78
Study 33765513 — intervention group
Group type: COMPARATOR
Intervention: lapatinib + trastuzumab (L+T)
Number of subjects: 8381
Study 33765513 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab followed by lapatinib (T→L)
Number of subjects: 8381
Study 33765513 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab (T)
Number of subjects: 8381
Study 32462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature model
Number of subjects: 379
Study 32462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic model combining radiomic signature and clinicoradiologic characteristics
Number of subjects: 379
Study 32462799 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic model
Number of subjects: 379
Study 35142091 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 461
Study 35142091 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care
Number of subjects: 461
Study 33284639 — intervention group
Group type: EXPERIMENTAL
Intervention: IBD-Home + standard care
Number of subjects: 158
Study 33284639 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 158
Study 35285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 300 mg
Number of subjects: 0
Study 35285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 600 mg
Number of subjects: 0
Study 35285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 1200 mg
Number of subjects: 0
Study 35285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid 1800 mg
Number of subjects: 0
Study 35285241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutezolid (all doses)
Number of subjects: 0
Study 33154022 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab alone
Number of subjects: 404
Study 33154022 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus lapatinib
Number of subjects: 404
Study 33154022 — intervention group
Group type: COMPARATOR
Intervention: Group A (DDFS event <12 months)
Number of subjects: 404
Study 33154022 — intervention group
Group type: COMPARATOR
Intervention: Group B (DDFS event >12 months)
Number of subjects: 404
Study 33154022 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison between groups A and B
Number of subjects: 404
Study 34006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tablet PrEP
Number of subjects: 429
Study 34006328 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP injection or implant
Number of subjects: 429
Study 34006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Military provider
Number of subjects: 429
Study 34006328 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone/telehealth visit
Number of subjects: 429
Study 34006328 — intervention group
Group type: EXPERIMENTAL
Intervention: On-base locations for lab evaluation and medication pick-up
Number of subjects: 429
Study 32129892 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressant (IS) dose reduction
Number of subjects: 283
Study 32881839 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (14.4% O2)
Number of subjects: 20
Study 32881839 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 20
Study 32881839 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia
Number of subjects: 20
Study 35177108 — intervention group
Group type: EXPERIMENTAL
Intervention: OPIOID (hydrocodone/acetaminophen 5/300 mg)
Number of subjects: 3
Study 35177108 — intervention group
Group type: COMPARATOR
Intervention: NON‐OPIOID (ibuprofen/acetaminophen 400/500 mg)
Number of subjects: 3
Study 33895428 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAR‐H1 assisted gait training (BAGT)
Number of subjects: 32
Study 33895428 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 32
Study 32223762 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention over 1 year
Number of subjects: 0
Study 32223762 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving traditional oral health information
Number of subjects: 0
Study 35146754 — intervention group
Group type: EXPERIMENTAL
Intervention: MotherWise (relationship education and brief case management/coaching program)
Number of subjects: 136
Study 35146754 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 136
Study 33508778 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ball warm-up (156 g)
Number of subjects: 13
Study 33508778 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier ball warm-up (171.6 g)
Number of subjects: 13
Study 33508778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter ball warm-up (140.4 g)
Number of subjects: 13
Study 33165570 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 2.5 mg/day
Number of subjects: 1001
Study 33165570 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone 5 mg/day
Number of subjects: 1001
Study 33165570 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone 50 mg/day
Number of subjects: 1001
Study 32750174 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) enema from a donor enriched in Lachnospiraceae and Ruminococcaceae
Number of subjects: 20
Study 32750174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32740676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Number of subjects: 101
Study 32740676 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 10 mg
Number of subjects: 101
Study 35576290 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration steroid therapy
Number of subjects: 150
Study 35576290 — intervention group
Group type: COMPARATOR
Intervention: Long duration steroid therapy
Number of subjects: 150
Study 33347019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin (160 mg/d)
Number of subjects: 56
Study 33347019 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 56
Study 34918967 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and metoclopramide
Number of subjects: 62
Study 34918967 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 62
Study 35704472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined group (study)
Number of subjects: 30
Study 35704472 — intervention group
Group type: COMPARATOR
Intervention: Vertical group (control)
Number of subjects: 30
Study 34682512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 26
Study 34682512 — intervention group
Group type: COMPARATOR
Intervention: Sham mask (control)
Number of subjects: 26
Study 33893252 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic mouthwash (G1)
Number of subjects: 63
Study 33893252 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice mouthwash (G2)
Number of subjects: 63
Study 33893252 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (G3)
Number of subjects: 63
Study 35986478 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Glass Ionomer Cement (GIC)
Number of subjects: 30
Study 35986478 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Resin‐modified Bioactive Resin (ACTIVA)
Number of subjects: 30
Study 35986478 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) with Composite Resin (CR)
Number of subjects: 30
Study 35986478 — intervention group
Group type: COMPARATOR
Intervention: Control (Sound dentine without SDF)
Number of subjects: 30
Study 32791940 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antiplatelet therapy
Number of subjects: 3154
Study 32791940 — intervention group
Group type: COMPARATOR
Intervention: No prior antiplatelet therapy
Number of subjects: 3154
Study 34799433 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered cigarettes
Number of subjects: 43
Study 34799433 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered cigarettes
Number of subjects: 43
Study 33530919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40
Study 33530919 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine
Number of subjects: 40
Study 32692952 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLC patch
Number of subjects: 28
Study 32692952 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique brace
Number of subjects: 28
Study 32692952 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior brace
Number of subjects: 28
Study 32692952 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLC patch, oblique brace, anterior brace
Number of subjects: 28
Study 36257847 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy closure without mechanical bowel preparation (MBP)
Number of subjects: 79
Study 36257847 — intervention group
Group type: COMPARATOR
Intervention: Colostomy closure with mechanical bowel preparation (MBP)
Number of subjects: 79
Study 35681510 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin
Number of subjects: 0
Study 35681510 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 0
Study 32089506 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous axillary access with vessel closure device
Number of subjects: 59
Study 35033226 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) alone
Number of subjects: 90
Study 35033226 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with low-dose radiotherapy (0.5 Gy delivered twice per day for 2 days during each of the first four cycles)
Number of subjects: 90
Study 35033226 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab (1500 mg intravenously every 4 weeks for a maximum of 13 cycles) plus tremelimumab (75 mg intravenously every 4 weeks for a maximum of four cycles) with hypofractionated radiotherapy (24 Gy total delivered over three 8-Gy fractions during the first cycle only)
Number of subjects: 90
Study 34328482 — intervention group
Group type: COMPARATOR
Intervention: Semilunar coronally positioned flap (SCPF) alone (control)
Number of subjects: 20
Study 34328482 — intervention group
Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap with free gingival graft (SCPF+FGG) (test)
Number of subjects: 20
Study 33272839 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy (four-week sessions over one month)
Number of subjects: 30
Study 33272839 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up (control group)
Number of subjects: 30
Study 33272839 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 30
Study 32081088 — intervention group
Group type: COMPARATOR
Intervention: Usual care questionnaires
Number of subjects: 80
Study 32081088 — intervention group
Group type: COMPARATOR
Intervention: Focus groups with healthcare professionals
Number of subjects: 80
Study 32081088 — intervention group
Group type: COMPARATOR
Intervention: Case note reviews
Number of subjects: 80
Study 32081088 — intervention group
Group type: COMPARATOR
Intervention: Triangulation of findings
Number of subjects: 80
Study 34865686 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary dance rhythm (12 weeks, twice a week, 45 minutes)
Number of subjects: 31
Study 34865686 — intervention group
Group type: EXPERIMENTAL
Intervention: Quaternary dance rhythm (12 weeks, twice a week, 45 minutes)
Number of subjects: 31
Study 33076997 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE mobility program implementation
Number of subjects: 8
Study 35172810 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic needle driver
Number of subjects: 10
Study 35172810 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexDex needle driver
Number of subjects: 10
Study 35172810 — intervention group
Group type: EXPERIMENTAL
Intervention: Da Vinci Si surgical system
Number of subjects: 10
Study 35172810 — intervention group
Group type: COMPARATOR
Intervention: FlexDex
Number of subjects: 10
Study 35172810 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic and Da Vinci Si
Number of subjects: 10
Study 33625574 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior approach (DA group)
Number of subjects: 44
Study 33625574 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral approach (PL group)
Number of subjects: 44
Study 32131964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention (two sessions: 5 minutes of structured advice and 15-20 minutes of behaviour change counselling, plus an optional booster session)
Number of subjects: 68
Study 32131964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioural intervention
Number of subjects: 68
Study 32131964 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 68
Study 34800427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg once per day until discharge)
Number of subjects: 7351
Study 34800427 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7351
Study 34800427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7351
Study 34027922 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressed Plyometric Training (PPT)
Number of subjects: 22
Study 34027922 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Progressed Plyometric Training (NPPT)
Number of subjects: 22
Study 34027922 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 35947940 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency awareness questionnaire for neurofeedback
Number of subjects: 20
Study 35947940 — intervention group
Group type: COMPARATOR
Intervention: Double-blinded group assignment
Number of subjects: 20
Study 33283377 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world cohort of VKA-treated AF patients with CKD
Number of subjects: 1108
Study 33283377 — intervention group
Group type: COMPARATOR
Intervention: AMADEUS trial cohort of VKA-treated AF patients with CKD
Number of subjects: 1108
Study 35410693 — intervention group
Group type: EXPERIMENTAL
Intervention: NETOIMS
Number of subjects: 77
Study 35410693 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia
Number of subjects: 77
Study 34460181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding SGLT2 inhibitors
Number of subjects: 0
Study 34460181 — intervention group
Group type: COMPARATOR
Intervention: Switching to GLP-1 receptor agonists (GLP-1 RAs)
Number of subjects: 0
Study 36204125 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NW Low-Glu® (4 capsules per day)
Number of subjects: 232
Study 36204125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NW Low-Glu® (5 capsules per day)
Number of subjects: 232
Study 36204125 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2000 mg per day)
Number of subjects: 232
Study 33337815 — intervention group
Group type: EXPERIMENTAL
Intervention: EtaBS (Enerceptan) 50 mg weekly for 32 weeks
Number of subjects: 150
Study 33337815 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg weekly for 32 weeks
Number of subjects: 150
Study 33337815 — intervention group
Group type: EXPERIMENTAL
Intervention: EtaBS
Number of subjects: 150
Study 33337815 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 150
Study 36383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (support from nonphysician care coordinators, electronic registers, and specialist‐supported case review) for 12 months, followed by 12 months of usual care or 24 months of usual care.
Number of subjects: 404
Study 36383487 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care integrated in clinical workflows.
Number of subjects: 404
Study 36383487 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 404
Study 34142415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 0
Study 34142415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33136471 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (60 mg/m2, days 1, 8, 15) plus cisplatin (60 mg/m2, day 1)
Number of subjects: 221
Study 33136471 — intervention group
Group type: COMPARATOR
Intervention: Etoposide (100 mg/m2, days 1‐3) plus cisplatin (80 mg/m2, day 1)
Number of subjects: 221
Study 33136471 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin
Number of subjects: 221
Study 33136471 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin
Number of subjects: 221
Study 35368946 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Decoction combined with docetaxel
Number of subjects: 92
Study 35368946 — intervention group
Group type: COMPARATOR
Intervention: Basic chemotherapy combined with docetaxel
Number of subjects: 92
Study 34791970 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 7 days
Number of subjects: 15
Study 34791970 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 14 days
Number of subjects: 15
Study 34791970 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 7 days during walking
Number of subjects: 15
Study 34791970 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (210 mg of anthocyanins) for 14 days during walking
Number of subjects: 15
Study 32112999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine cream
Number of subjects: 190
Study 32112999 — intervention group
Group type: COMPARATOR
Intervention: Rectal meloxicam suppository 15 mg
Number of subjects: 190
Study 35455529 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy via telerehabilitation (5 sessions per week, 1 hour each for 3 weeks)
Number of subjects: 52
Study 35455529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 32030559 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30
Study 32030559 — intervention group
Group type: EXPERIMENTAL
Intervention: 740 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30
Study 32030559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1110 MBq of 99mTc‐TRODAT‐1
Number of subjects: 30
Study 34237746 — intervention group
Group type: EXPERIMENTAL
Intervention: Shopping Exercise (SE)
Number of subjects: 240
Study 34237746 — intervention group
Group type: EXPERIMENTAL
Intervention: Brandt-Daroff (BD) exercise
Number of subjects: 240
Study 34237746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 34872405 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS (n=19)
Number of subjects: 40
Study 34872405 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n=21)
Number of subjects: 40